European and US regulators approve AbbVie's new combo for all hepatitis C genotypes
Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection
US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment
New pangenotypic hepatitis C drug combinations recommended for approval in the European Union
Triple combination cures most hepatitis C patients with prior DAA treatment failure
AbbVie combination cures 95% of genotype 3 hepatitis C
New AbbVie hepatitis C combination cures 99% of people with cirrhosis
Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals
Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study
